Cresset Asset Management LLC acquired a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,911 shares of the company's stock, valued at approximately $251,000. Cresset Asset Management LLC owned about 0.19% of Palvella Therapeutics at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth approximately $256,000. BML Capital Management LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth approximately $506,000. Geode Capital Management LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth approximately $171,000. Nantahala Capital Management LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth approximately $3,001,000. Finally, Adams Street Partners LLC acquired a new stake in Palvella Therapeutics during the fourth quarter worth approximately $4,916,000. 40.11% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, Director George M. Jenkins purchased 2,500 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average price of $20.13 per share, with a total value of $50,325.00. Following the transaction, the director now directly owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This represents a 1.38% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by corporate insiders.
Palvella Therapeutics Price Performance
Palvella Therapeutics stock traded up $1.61 during mid-day trading on Friday, reaching $23.72. 138,230 shares of the company's stock were exchanged, compared to its average volume of 68,642. The business has a fifty day simple moving average of $24.12. The company has a market capitalization of $261.94 million, a price-to-earnings ratio of -1.96 and a beta of 0.10. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $2.66. As a group, equities research analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on PVLA shares. Scotiabank started coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Canaccord Genuity Group reduced their price objective on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, May 16th. TD Cowen began coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective for the company. Stifel Nicolaus began coverage on Palvella Therapeutics in a research report on Wednesday, March 26th. They set a "buy" rating and a $45.00 target price on the stock. Finally, Jones Trading began coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $45.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $46.29.
Read Our Latest Stock Analysis on Palvella Therapeutics
About Palvella Therapeutics
(
Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
